[Sinovac Holds 2012 Annual General Meeting of Shareholders BEIJING, Aug. 23, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2012 Annual General Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The required quorum, a majority of the common shares outstanding, was voted] []
[Sinovac Schedules 2012 Annual Meeting of Shareholders BEIJING, July 16, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2012 Annual Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road,] [July 16, 2012 Dear Shareholder: You are cordially invited to attend the 2012 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 22, 2012, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in Antigua at No. 6 Temple Street, St.] []
[Sinovac Schedules 2012 Annual Meeting of Shareholders BEIJING, July 16, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2012 Annual Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road,] [July 16, 2012 Dear Shareholder: You are cordially invited to attend the 2012 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 22, 2012, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in Antigua at No. 6 Temple Street, St.] []
[Sinovac Names Danny Chung Chief Financial Officer SVA Beijing – May 14, 2012 – Sinovac Biotech Ltd. (Nasdaq: “Mr. Chung possesses the relevant experiences and credentials, which meet the Company’s needs,” said Dr. Weidong Yin, Chairman and CEO. “Beyond his audit and accounting expertise, Mr. Chung has proven adept in the financial management of Chinese divisions of multinational companies. We] []
[Sinovac Names Danny Chung Chief Financial Officer SVA Beijing – May 14, 2012 – Sinovac Biotech Ltd. (Nasdaq: “Mr. Chung possesses the relevant experiences and credentials, which meet the Company’s needs,” said Dr. Weidong Yin, Chairman and CEO. “Beyond his audit and accounting expertise, Mr. Chung has proven adept in the financial management of Chinese divisions of multinational companies. We] []
[Sinovac Reports Unaudited First Quarter 2012 Financial Results – Conference call scheduled for Tuesday, May 15, 2012 at 8:00 AM EDT – – Sinovac Biotech Ltd. ( today its unaudited first quarter Beijing – May 15, 2012 Financial Highlights (year-over-year comparisons to first quarter 2011) · Sales increased 30.3% to $6.0 million, with Bilive vaccines sales up 92.4%. · Gross] []
[Sinovac Reports Unaudited First Quarter 2012 Financial Results – Conference call scheduled for Tuesday, May 15, 2012 at 8:00 AM EDT – – Sinovac Biotech Ltd. ( today its unaudited first quarter Beijing – May 15, 2012 Financial Highlights (year-over-year comparisons to first quarter 2011) · Sales increased 30.3% to $6.0 million, with Bilive vaccines sales up 92.4%. · Gross] []
[None (Title of Class) Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 54,773,961 common shares as of December 31, 2011 Yes o No x Yes o No x Yes x No o Yes x No o Large accelerated filer] [SINOVAC BIOTECH LTD. ANTIGUA AND BARBUDA The International Business Corporations Act, 1982 No. 28 of 1982 Cap. 222 Vol. 5 of the Revised Laws of Antigua 1992 Edition A Company Limited by Shares ARTICLES OF INCORPORATION OF SINOVAC BIOTECH LTD. Amended on March 21, 2006 ARTICLE I. NAME The name of the Corporation is SINOVAC BIOTECH LTD. ARTICLE II. REGISTERED] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 6 a12-6625_1ex13d1.htm EX-13.1] [Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 7 a12-6625_1ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 12, 2012, with respect to the consolidated financial statements of Sinovac Biotech Ltd. and the effectiveness of internal control over financial reporting]
[Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results - Conference call scheduled for Thursday, March 29, 2012 at 8:00 AM EDT - BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and preliminary full year financial results for the period] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F ¨ SINOVAC BIOTECH LTD. 6-K 1 v308765_6k.htm 6-K]
[Sinovac Announces Director Appointment BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the appointment of Mr. Meng Mei as an independent director to fill the vacancy created by the resignation of Ms. Chup Hung Mok. Mr. Mei has also been appointed as the chairman of Sinovac's compensation] [Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine Vaccine BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that the positive Phase I clinical data for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F ¨ SINOVAC BIOTECH LTD. 6-K 1 v301323_6k.htm FORM 6-K]
